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Prioritizing Genetic Variants for Causality
on the Basis of Preferential Linkage Disequilibrium
Qianqian Zhu,1,2,* Dongliang Ge,1,3 Erin L. Heinzen,1 Samuel P. Dickson,1,4 Thomas J. Urban,1
Mingfu Zhu,1 Jessica M. Maia,1 Min He,1 Qian Zhao,1 Kevin V. Shianna,1 and David B. Goldstein1,*
To date, the widely used genome-wide association studies (GWASs) of the human genome have reported thousands of variants that are
significantly associated with various human traits. However, in the vast majority of these cases, the causal variants responsible for the
observed associations remain unknown. In order to facilitate the identification of causal variants, we designed a simple computational
method called the ‘‘preferential linkage disequilibrium (LD)’’ approach, which follows the variants discovered by GWASs to pinpoint the
causal variants, even if they are rare compared with the discovery variants. The approach is based on the hypothesis that the GWAS-
discovered variant is better at tagging the causal variants than are most other variants evaluated in the original GWAS. Applying the
preferential LD approach to the GWAS signals of five human traits for which the causal variants are already known, we successfully
placed the known causal variants among the top ten candidates in the majority of these cases. Application of this method to additional
GWASs, including those of hepatitis C virus treatment response, plasma levels of clotting factors, and late-onset Alzheimer disease, has
led to the identification of a number of promising candidate causal variants. This method represents a useful tool for delineating causal
variants by bringing together GWAS signals and the rapidly accumulating variant data from next-generation sequencing.Introduction
After the first wave of genome-wide association studies
(GWASs), thousands of common variants associated with
hundreds of human traits have been identified.1 Although
these findings shed light on the genetic architectures of
human traits, the variants reaching genome-wide signifi-
cance for any particular phenotype cumulatively explain
only a small portion of the phenotypic variation.2 More-
over, in most cases the variants identified by GWASs are
proxies of the causal variants that still remain to be discov-
ered.3 Under the ‘‘common disease, common variant’’
hypothesis, one frequently used approach for causal-
variant discovery is to look for the variants in the genomic
region showing strong linkage disequilibrium (LD) (e.g., r2
> 0.8) with the variant discovered by the GWAS. However,
this approach will not work well when the allelic frequen-
cies of the causal variants are below the frequencies of the
common variants used for describing ‘‘blocks’’ of LD. For
example, the well-documented causal variants of Crohn
disease (MIM 266600) in NOD2 (MIM 605956)4 and the
causal variants of anemia in individuals treated for chronic
hepatitis C in ITPA (MIM 147520)5 are in both cases
considerablymore rare than the disease-associated variants
identified by GWASs. As a result, their LD with the GWAS-
discovered variants is, at best, moderate (r2 < 0.5). In fact,
there are a number of examples where the signals identi-
fied in GWASs are caused or contributed by variants with
substantially lower allele frequencies than the GWAS-
discovered variants4–8 (Table 1). These experiences suggest
that it would be valuable to establish efficient algorithms1Center for Human Genome Variation, Duke University School of Medicine,
Roswell Park Cancer Institute, Buffalo, NY 14263, USA
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422 The American Journal of Human Genetics 91, 422–434, Septembfor systematically searching for variants that contribute
to GWAS signals but are substantially rarer than the
discovery variants from GWASs. This effort should be
viewed as complementary to widely performed discovery
efforts that assume that the causal variant is similar in
frequency to the GWAS-discovered variant12–18 and as an
addition to the recently increasing screens for rare causal
variants.6–8,19–23 We also note that the effort to make effec-
tive use of GWAS signals to look for causal variants makes
no assumptions or claims about the collective importance
of synthetic associations to GWAS signals.24,25 Rather, we
recognize that some GWAS signals will be synthetic, and
for this reason, discovery strategies well suited to this possi-
bility are needed.26 It is also worth noting that even in
cases where a given genomic region carries both common
and rare causal variants, the approach described here
might be especially helpful for identifying any rare causal
variants that contribute to the original GWAS signal. In
theory, our approach can also be applied to the situation
where the causal variant has a similar frequency to the
GWAS-discovered variant. In this case, however, we antic-
ipate little benefit from our approach because the fact that
variants in the same frequency range and their LD proper-
ties with the discovery variant will mostly already be
known makes it possible to directly consider all variants
in high LD with the discovery variant.
To prioritize candidate causal variants in genomic
regions surrounding GWAS signals, especially when the
LD between the causal variants and the GWAS-discovered
variant is relatively weak, we designed a computational
method called the ‘‘preferential LD’’ approach. ThisDurham, NC 27708, USA; 2Department of Biostatistics and Bioinformatics,
(D.B.G.)
y of Human Genetics. All rights reserved.
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Table 1. Variants Responsible for the Associations Detected by GWASs
Phenotype Gene
Causal Variants GWAS Variants
ReferencesName MAF Name MAF
Crohn disease NOD2 rs2066844 4.1% rs17221417 28.7% Wang et al.4
rs2066845 1.5%
rs2066847 1.9%
Ribavirin-induced
hemolytic anemia
ITPA rs1127354 7.6% rs6051702 19.4% Fellay et al.5
rs7270101 12.3%
Therapeutic warfarin
dose
CYP2C9 rs1799853 11% rs4917639 18% Takeuchi et al.9
and Wadelius et al.10
rs1057910 7%
Bladder cancer UGT1A6 rs17863783 2.5% rs11892031 8.5% Tang et al.11
Low-density lipoprotein
cholesterol
PCSK9 rs11591147 3.7% rs11206510 24.3% Sanna et al.8
Sick sinus syndrome MYH6 c.2161C>Ta 0.38% rs28730774 1% Holm et al.6
Ovarian cancer BRIP1 c.2040_2041insTTb 0.41% rs34289250 0.89% Rafnar et al.7
The following abbreviations are used: GWAS, genome-wide association study; and MAF, minor allele frequency.
aRefSeq NM_002471.3; reference genome build 36.
bRefSeq NM_032043.2; reference genome build 36.approach is based upon the idea that when the allelic
frequency of a causal variant is lower than that of the
GWAS-discovered variant, the LD between them, although
relatively weak, will be larger than the LD values between
the causal variant and most other variants interrogated
in the GWAS. Thus, instead of simply looking for any
candidate causal variants in high LD with the GWAS-
discovered variant, as is typical, we focus on those variants
that show the strongest preferential LD with the GWAS-
discovered variant, regardless of the absolute magnitude
of the LD. We calculated the LD values by using genotypes
from 479 individuals of European ancestry; these geno-
types included a combination of those that were from
whole-genome sequencing, whole-exome sequencing,
chip genotyping, and imputation. Starting with a variant
discovered by the GWAS (this variant is called here the
‘‘discovery’’ variant), we first applied our approach to
several examples where the causal variants are known.
All the cases we considered had the property that the iden-
tified causal variants were rarer than the discovery variant.
Our approach successfully identified the known causal
variants of Crohn disease, hemolytic anemia following
treatment for hepatitis C virus (HCV), therapeutic warfarin
dose (MIM 122700), bladder cancer (MIM 109800), and
hearing loss. This proof of concept strongly suggests that
our approach will succeed in identifying unknown cases
in which the causal variants are rarer than discovery
ones, regardless of how often they might occur overall in
GWAS signals. We applied this approach to 33 indepen-
dent GWAS discovery variants across three different traits
and report the leading candidate causal variants from the
analysis. Included in this list of possible causal variants
are a number of suggestive candidates that might
contribute to the identified GWAS signals. The resultsThe Americanand scripts of the preferential LD approach are available
at our website (Web Resources).Material and Methods
Study Subjects
All samples collected at Duke were approved by the local institu-
tional review board (IRB) so they could be used as controls. All
samples from outside institutions were received in a deidentified
state. All deidentified samples were received under a Duke IRB
exemption and were therefore classified as nonhuman subjects.Sequencing
The genomic DNA of 75 individuals was directly sequenced with
the Illumina Genome Analyzer IIx or the HiSeq 2000, whereas
the genomic DNA of the other 282 and 122 individuals was
captured on the Agilent SureSelect Human All Exon 37 Mb Kit
and 50 Mb Kit, respectively, before Illumina sequencing. The
average coverage of whole-genome- and whole-exome-sequenced
samples was 343 and 783, respectively. The sequence reads were
aligned to the reference genome (NCBI build 36, release 50) with
the Burrows-Wheeler Aligner.27 SAMtools28 was used for calling
genotypes and identifying single-nucleotide variants (SNVs). For
quality control, SNVswere required to pass four filters: a consensus
quality score of no less than 20, a SNP quality score of no less than
20, no fewer than three reads supporting the variant allele, and
a maximum read depth of 500. For exome-sequencing samples,
we further required at least 90% of the capture regions in each
sample to be sequenced with R53 coverage. When no variant
call was made at a particular position of a sample, we assumed
that the genotype was a homozygous reference if the position
was covered by no fewer than eight reads; otherwise, we consid-
ered the genotype to be missing at that position. For each of the
three sequencing platforms, SNVs with a missing rate > 10%
were removed.Journal of Human Genetics 91, 422–434, September 7, 2012 423
Genotyping and Imputation
In order to expand the number of variants in exome-sequencing
samples, we performed microarray genotyping and computa-
tional imputation in these samples. Specifically, a total of 298
and 106 exome-sequencing samples were genotyped with the Illu-
mina Human610-Quad BeadChip and Illumina Human1M-Duo
BeadChip, respectively. For each genotyping platform, SNPs
with a missing rate > 10% were removed and the set of the geno-
types satisfying a minor allele frequency (MAF) R 1%, a Hardy-
Weinberg equilibrium (HWE) p value > 1 3 106, and a SNP
missing rate % 5% were used for imputation with MACH29,30
(50 rounds; all other parameters were kept at their default values).
We used two reference panels in the imputation: HapMap II
phased CEU (Utah residents with ancestry from northern and
western Europe from the CEPH collection) chromosomes and
HapMap III phased European-ancestry chromosomes (CEU þ
TSI [Toscans in Italy]). After filtering out SNVs that were not reli-
ably imputed (MACH-estimated r2 < 0.3), we merged the imputed
genotypes from the two reference panels by using PLINK.31 If
a SNV was imputed from both panels, the genotypes from the
HapMap III haplotypes overwrote the genotypes from the
HapMap II haplotypes. The imputed genotypes were then inte-
grated with chip genotypes from genotyping arrays. The chip
genotypes were overwritten by imputed genotypes only when
they were missing. Next, the integrated genotypes of the 298
samples genotyped with the Illumina Human610-Quad BeadChip
were combined with the integrated genotypes of the 106 samples
genotyped with the Illumina Human1M-Duo BeadChip. Plat-
form-specific SNPs were removed. Finally, we merged the geno-
types obtained from sequencing in all 479 samples with the geno-
types integrated from chip genotyping and imputation in the 404
exome-sequencing samples. The sequencing genotypes were over-
written only when they were missing. After removing SNVs with
a MAF equal to zero, we obtained a total of 13,418,055 autosomal
SNVs in the 479 samples.The Preferential LD Approach
Step 1. Collecting Candidate SNVs around the Discovery SNP
From our SNV collection described above, we first extracted the
genotypes of SNVs that had been evaluated in the original
GWAS, which included all SNVs in the genotyping platform(s)
of the GWAS and SNVs in the imputation reference panel if the
GWAS was a meta-analysis. The extracted SNVs that were not on
the same chromosome as the discovery SNP were removed. The re-
maining SNVs were also filtered byMAF and a HWE test. For meta-
GWASs and GWASs for which the cutoff values were not reported
in their publications, we applied the commonly used cutoffs
(MAFR 1% and HWE p value > 1 3 106); otherwise, the cutoff
values reported in the publications were used.We called this group
of SNVs ‘‘GWAS SNVs.’’ We then collected a group of ‘‘candidate
SNVs’’ from our SNV collection by using the following criteria:
500 kb upstream and downstream of the discovery SNP, MAF %
the MAF of the discovery SNP, MAF % 15%, HWE p value > 1 3
106, r2 with the discovery SNP > 0.005, and absence from the
GWAS SNV group. The pairwise LD was calculated with Haplo-
view.32 Similar results were obtained when we extended the
distance to 1 Mb around the discovery SNP (data not shown).
We observed little effect on the approach’s ability to identify
causal variants when we changed the MAF cutoff of the candidate
SNVs, even when the candidate SNVs were not required to be as
common as the discovery SNP (Table S1, available online).424 The American Journal of Human Genetics 91, 422–434, SeptembStep 2. Identifying Candidate SNVs in Preferential LD with the Discovery
SNP
For each candidate SNV, we calculated the statistic ‘‘preferential
LD’’ (PLD) and filtered out the candidate SNVs that could not be
specifically tagged by the discovery SNP by requiring the value of
PLD to be %0.05. Specifically, for the i
th candidate SNV, PLD;i ¼PN
j¼1Iðr2ijRr2i Þ=N, where I is an indicator function, N is the number
of SNVs in the GWAS SNV group, rij
2 is the r2 between the ith
candidate SNV and the jth GWAS SNV, and ri
2 is the r2 between
the ith candidate SNV and the discovery SNP. PLD,i assesses the
proportion of GWAS SNVs that have equal or higher r2 with the
ith SNV than the r2 between the ith SNV and the discovery SNP.
Step 3. Identifying Candidate SNVs Whose LD with the Discovery SNP Is
Not Random
For each of the remaining candidate SNVs from step 2, we per-
formed a permutation test to determine whether its r2 with the
discovery SNP was due to chance. Specifically, we permuted the
genotypes of the candidate SNV and the discovery SNP 2,000
times and calculated the empirical p value as the fraction of
permutations for which the r2 calculated from the permuted geno-
types was equal to or greater than the observed r2. The empirical p
value estimates the probability of observing the same or better r2
value for two random variants with the same frequencies as the
two particular variants. Only the candidate SNVs with an empir-
ical p value % 0.1 were kept. We used a less stringent cutoff here
to compensate for the smaller sample size of SNVs observed only
in whole-genome samples.
Step 4. Prioritizing Candidate SNVs
Finally, we prioritized the candidate SNVs that were preferen-
tially tagged by the discovery SNP and functionally important
by using a sorting score (S). For the ith candidate SNV, Si ¼
w 3 PhastConsi þ ð1wÞ 3 ð1 ðPLD;i=0:05ÞÞ, where PhastConsi
is the PhastCons score33 for primates at the corresponding
genomic position, w is the weight for the PhastCons score (by
default, w ¼ 0.3), and PLD,i is the corresponding preferential LD
value described above. We noticed that as long as the PhastCons
score is incorporated into the sorting score, changing the weight
of the PhastCons score only marginally affects the ranking of the
known causal variants, except for one case in which the causal
variant is very rare (Table S2). The PhastCons scores were down-
loaded from the UCSC Genome Browser (Web Resources), and
a larger value corresponds to greater selective constraint. Using
PhyloP34 score instead of PhastCons score was found to generate
overall similar results in ranking the known causal variants (Table
S3). Candidate SNVs were ranked in descending order of the sort-
ing score. In order to estimate the statistical significance of the
sorting scores, we randomly drew 2,000 SNVs in the 500 kb neigh-
borhood of the discovery SNP and calculated their sorting scores.
Because the majority of these randomly selected SNVs are not
causal variants, the distribution of their sorting scores can be
used for estimating the null distribution of S. Therefore, the
p value of the sorting score corresponding to the ith candidate
SNV is calculated as the fraction of randomly selected SNVs with
a sorting score equal to or greater than Si. We considered the candi-
date SNVs with p values% 0.05 as the candidate causal variants.
Preferential LD Application on the 1000 Genomes
Project Data
We obtained the phased genotypes from the 1000 Genomes
Project35 phase I integrated variant release (March 2012 release)
(Web Resources) and extracted SNVs from 379 individuals of Euro-
pean ancestry. SNVs with MAFs equal to zero were removed, ander 7, 2012
Figure 1. Flow Chart of Integrating SNV
Genotypes from 479 Samplesthe coordinates of the remaining SNVs were converted from hg19
to hg18 with liftOver (Web Resources). At the end, we obtained
a total of 15,845,467 autosomal SNVs. We applied the preferential
LD approach to this data set by using the same parameters as indi-
cated above.
Association Test of Candidate SNVs with HCV
Treatment Response
We merged the SNV genotypes from whole-genome sequencing,
whole-exome sequencing, and chip genotyping for all 479
samples (missing rate per SNV % 0.1, and HWE p value > 1 3
106). MACH29,30 was then used for phasing the 2 Mb region
centered on rs12979860 in these samples and for imputing the
SNVs from the phased haplotypes to the GWAS cohort (missing
rate per SNP % 0.05, MAF R 1%, and HWE p value > 1 3 106).
Default MACH parameters were used, but the number of rounds
was set to 50. At the step of estimating model parameters during
imputation, 400 individuals randomly selected from the GWAS
cohort were used. We also performed phasing and imputation by
using SNVs from the whole-genome sequencing of 75 samples
to impute SNVs only available through whole-genome
sequencing. The association test between the imputed candidate
SNVs and HCV treatment response in the GWAS cohort was per-
formed with PLINK31 on the basis of the dosage data.Results
In order to have the largest sample size possible with our
data, we integrated the genotypes from 75 whole-genome-
sequenced individuals with the genotypes from 404 whole-
exome-sequenced individuals. Because most of the SNPs
analyzed in GWASs are missing in exome-sequenced
samples, we genotyped these samples by using Illumina
high-density arrays and imputed SNPs from HapMap II and
HapMap III haplotypes. We obtained a total of 13,418,055
autosomal SNVs after integrating genotypes fromall of these
sources (Figure 1, seeMaterial andMethods). For SNVs found
inbothwhole-genomeandwhole-exome samples, their esti-
mated MAF can be as low as 0.10% and we have more than
80% power to detect alleles with a population frequencyR
0.17%. For SNVs only observed in the whole-genome
samples, the lowest estimated MAF is 0.67% and we have
greater than 80% power to detect alleles with a frequency
R 1.07% (Figure S1).The American Journal of Human GeneThe Preferential LD Approach
Our approach to identifying candi-
date causal variants consists of four
major steps (Figure 2, see Material
and Methods). The input to this
approach includes a SNP reported to
be significantly associated with the
trait of interest (discovery SNP) in
a GWAS and the genotyping plat-form(s) used in the GWAS, as well as the reference panel
used for imputation if the GWAS is a meta-analysis. First,
we identified SNVs that were in a 1 Mb interval centered
on the discovery SNP, had not been evaluated in the
GWAS of interest, were rarer than the discovery SNP, and
were not more common than 15% (given that variants
more common than this frequency range probably do
not have important functions36). Second, we identified
the candidate SNVs that were preferentially tagged by the
discovery SNP by calculating the PLD statistic. This statistic
estimates the percentage of GWAS SNPs that can tag the
candidate SNV better than or as well as the discovery
SNP. Third, we performed permutation tests and kept the
candidate SNVs whose LD with the discovery SNP was
not due to chance. Finally, we prioritized the candidate
SNVs that were preferentially tagged by the discovery
SNP and functionally important on the basis of a sorting
score that incorporates both the preferential LD statistic
and evolutionary conservation. Candidate SNVs with
statistically significant sorting scores were considered to
be the candidates for causal variants driving the associa-
tion between the discovery SNP and the phenotype of
interest.
Proof of Concept: The Preferential LD Approach
Identifies Known Causal Variants
In order to evaluate the effectiveness of our approach, we
applied it to the GWAS of five different human traits for
which the causal variants have been reported and are
present in our samples. It is important to appreciate that
in all but one case, the known causal variants not only
are identified as candidates out of all identified SNVs in
the relevant intervals but also receive very high priority
scores—they always rank among the top ten SNVs. For
the only exception where the causal variant is not
conserved according to the PhastCons score, the particular
variant is still among the top 25 candidates.
Crohn Disease
Crohn disease is one of the few cases for which the causal
variants for GWAS signals are known; these include two
nonsynonymous variants (rs2066844 and rs2066845)
and one frameshift variant (rs2066847) caused by a cyto-
sine insertion in NOD2.37–41 The GWAS carried out bytics 91, 422–434, September 7, 2012 425
Figure 2. Flow Chart of the Preferential LD Approachthe Wellcome Trust Case Control Consortium (WTCCC)
detected a common SNP (rs17221417) that is significantly
associated with Crohn disease at the NOD2 locus.42
However, the effect size of this discovery SNP is smaller
than the effect size of any one of the three causal variants,
and the genetic risk explained by this discovery SNP is
significantly lower than the genetic risk explained by the
three causal variants.4 We applied our preferential LD
approach to search for candidate causal variants in the
1 Mb interval centered on rs17221417, which was identi-
fied by the WTCCC GWAS with the Affymetrix GeneChip
Human Mapping 500K Array Set for genotyping. Because
our variant collection only contained SNVs, we were not
able to evaluate the causal insertion variant rs2066847.
In step 1, we collected a total of 1,658 candidate SNVs
in the neighborhood (500 kb in each direction) of
rs17221417. Among them, 152 were found to be in prefer-
ential LD with rs17221417 in step 2. After filtering out
SNVs in nonsignificant LD with rs17221417, we obtained
141 candidate SNVs in step 3. Fifty-six of these SNVs
have significant sorting scores, which mean that no more
than 5% of 2,000 randomly selected SNVs in the same
1 Mb neighborhood have equal or better scores. The two
known causal variants, rs2066844 and rs2066845, were
ranked as the top two candidates by our sorting score in
the final step (Table 2). Therefore, starting from the
discovery SNP (rs17221417) identified by the WTCCC
GWAS, we successfully identified two causal variants of426 The American Journal of Human Genetics 91, 422–434, SeptembCrohn disease by using this preferential LD approach.
When we applied our approach to a different discovery
SNP (rs2076756) in the same locus, which was reported
to be significantly associated (p value < 5 3 108) with
Crohn disease by another GWAS,43 we also identified the
two known causal variants as the top two candidates
(Table 2).
Ribavirin-Induced Anemia
Previously, we performed a GWAS on ribavirin-induced
hemolytic anemia in individuals treated for chronic HCV
infection by using the Illumina Human610-Quad Bead-
Chip, and we identified rs6051702 to be strongly associ-
ated with treatment-induced reduction in hemoglobin
levels.5 The causal variants are two nonsynonymous ITPA
variants (rs1127354 and rs7270101) that cause the accu-
mulation of inosine triphosphate, which is used in place
of guanosine triphosphate during adenosine triphosphate
(ATP) biosynthesis, and that therefore protect individuals
from erythrocyte ATP reduction and anemia during treat-
ment.44 By using our preferential LD approach to follow
the GWAS discovery SNP, we identified a final set of 53
candidate SNVs from a total of 1,289 SNVs around the
associated locus; the two causal variants, rs1127354 and
rs7270101, were ranked first and second, respectively
(Table 2).
Therapeutic Warfarin Dose
In a GWAS of therapeutic warfarin dose with the Illumina
HumanCNV370 BeadChip, rs4917639 is observed as theer 7, 2012
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The Americanstrongest phenotype-associated SNP at the CYP2C9 (MIM
601130) locus.9 This association is found to be driven by
two rarer nonsynonymous variants (rs1799853 and
rs1057910) that impair warfarin metabolism.9,10,26 We
applied the preferential LD approach to this case. Starting
from 1,966 SNVs in the 1 Mb interval centered on
rs4917639, we identified 154 candidates in the end, and
the known causal variant, rs1799853, was the second
best candidate (Table 2). The other causal variant,
rs1057910, was not considered by the preferential LD
approach because it is present in the HumanCNV370
chip and was tested in the original GWAS.
Bladder Cancer
Recently, Tang et al. found a rare synonymous UGT1A6
(MIM 606431) variant (rs17863783) that completely
explains the association between bladder cancer and the
GWAS-discovered SNP (rs11892031).11 The rare variant,
rs17863783, was suggested to change UGT1A6 mRNA
expression and affect the removal of carcinogens from
the bladder.11 We used the preferential LD approach to
follow the discovery SNP, rs11892031, identified by the
bladder cancer GWAS, which used the SNPs found in
both the Illumina Human1M-Duo and Human610-Quad
BeadChips.45 In the end, 131 out of 516 SNVs found
around the discovery SNP were identified as candidates.
The causal variant, rs17863783, was ranked as the 23rd
best candidate as a result of the low PhastCons score at
the corresponding genomic position.
Hearing Loss
Hearing loss is a complex human disease that is largely
caused by rare mutations in the GJB2 (MIM 121011)-
GJB6 (MIM 604418) locus.46,47 For example, the most
common causal variant in GJB2 (rs80338939; c.35delG
[p.Gly12Valfs]) occurs with an allele frequency of only
1.25% in European Americans.48 In a recent hearing-loss
GWAS with the Illumina HumanHap550 BeadChip, two
independent common SNPs (rs870729 and rs7329467) in
the GJB2-GJB6 locus were found to be significantly associ-
ated with the phenotype.24 The discovery SNP rs870729
has been found to be in high LD (D0R 0.95) with a number
of known causal GJB2 variants, including c.35delG
(p.Gly12Valfs), c.167delT (p.Leu56Argfs), c.109G>A
(p.Val37Ile), c.269T>C (p.Leu90Pro), and c.101T>C
(p.Met34Thr).4 Because c.35delG (p.Gly12Valfs) and
c.167delT (p.Leu56Argfs) are deletion variants and
c.109G>A (p.Val37Ile) was not observed in the 479
samples we used, they were not included in our analysis.
Interestingly, when we used the preferential LD approach
to follow rs870729, known causal variant c.269T>C
(p.Leu90Pro) (rs80338945)49–51 was ranked as fifth out of
the final 162 candidate SNVs. On the other hand, when
we followed the other discovery SNP rs7329467, another
causal variant, c.101T>C (p.Met34Thr) (rs35887622),51–54
was found to be the sixth best candidate among a final
set of 82. Therefore, our approach has identified the
hearing-loss causal variants that contribute to the reported
genome-wide associations. Our results also suggest that inJournal of Human Genetics 91, 422–434, September 7, 2012 427
Table 3. The Ranking of the Causal Variants via Different Statistics
Phenotype
Discovery
SNP
Number of
Candidate SNVsa Causal SNV MAF
Rank of the Causal SNVb
D0 r2 PLD PhastCons Sorting Score
Crohn disease rs17221417 1,658 rs2066844 0.048 1,306 26 34 42 1
rs2066845 0.023 1,306 89 38 35 2
Crohn disease rs2076756 1,523 rs2066845 0.023 1,195 68 27 31 1
rs2066844 0.048 1,195 13 19 37 2
Ribavirin-induced
hemolytic anemia
rs6051702 1,289 rs1127354 0.081 829 86 49 1 1
rs7270101 0.128 776 22 39 10 2
Therapeutic warfarin
dose
rs4917639 1,966 rs1799853 0.134 1,586 7 26 10 2
Bladder cancer rs11892031 516 rs17863783 0.015 256 102 20 73 37c
Hearing loss rs870729 1,477 rs80338945 0.002 964 1145 150 7 5
Hearing loss rs7329467 999 rs35887622 0.015 574 55 12 70 6
The following abbreviations are used: SNV, single-nucleotide variant; MAF, minor allele frequency; and PLD, preferential linkage disequilibrium.
aCandidate SNVs are the ones obtained at step 1 of the preferential LD approach.
bThe rank of the causal variant is the number of candidate SNVs with an equal or better value of the corresponding statistic than the causal variant.
cThe rank of rs17863783 shown here is different from the rank shown on Table 2 because the 14 candidate SNVs with larger sorting scores than rs17863783 did
not pass the permutation test at step 3.addition to themost significant phenotype-associated SNP,
the other independent phenotype-associated SNPs are also
worth investigating for the identification of additional
causal variants.
We also applied the preferential LD approach to the SNV
genotypes in 379 European-ancestry samples from the
1000 Genomes Project and found that the results are
highly consistent for five of the eight known causal vari-
ants (Table S4). The causal variant (rs80338945) of hearing
loss was absent from the 1000 Genomes Project data,
whereas the causal variants of bladder cancer and hearing
loss, rs17863783 and rs35887622, were ranked as 40 and
60, respectively, as opposed to 23 and 6, respectively,
with our own samples. We speculated that the discrepancy
might be due to the lower sample size of the 1000
Genomes Project data. The causal variant (rs80338945)
not available from the 1000 Genomes Project data is the
most rare (MAF¼ 0.2% on the basis of our samples) among
all eight known causal variants, whereas the other two
causal variants that showed decreased performance with
the 1000 Genomes Project data are the second and third
most rare (MAF % 2%).
The Contribution of LD Measures
To compare the performance of different weighting
schemes in identifying causal variants, we evaluated rank-
ings of known causal variants on the basis of the magni-
tude of two different LD measures (D0 and r2) and
compared these with PLD (Table 3). We found that D
0 was
the worst measure in terms of prioritizing the causal vari-
ants. PLD overall performs better than r
2, especially when
the causal variant is rare (e.g., MAF < 3%). For the three
most rare causal variants evaluated here (rs80338945,428 The American Journal of Human Genetics 91, 422–434, Septembrs35887622, and rs17863783), their rankings improved
from 1,145, 55, and 102 to 150, 12, and 20, respectively,
when we used PLD instead of r
2. Presumably, the key reason
for the superiority of PLD is that it not only identifies SNVs
whose LD is the highest with the discovery variant
compared to other variants interrogated in the GWAS but
also excludes from consideration SNVs that are in nonspe-
cific LD with many GWAS variants. The combination of
the conservation score with the preferential LD statistic
further boosted the known causal variants to the very
top of the candidate list in most cases, which highlights
the importance of incorporating conservation score into
the discovery of causal variants.55
Identifying New Candidate Causal Variants
We have so far applied the preferential LD approach to 33
independent discovery variants reported in the GWAS of
three different human traits: HCV treatment response
(MIM 609532), plasma level of coagulation factors, and
Alzheimer disease (AD [MIM 104300]). The results of the
candidate causal variants are tabulated and available at
our website (Web Resources) for the community to investi-
gate. We summarized the candidate causal variants of
particular interest in Table 4 and describe them below.
HCV Treatment Response
Ge et al. previously performed a GWAS on individuals
chronically infected by genotype 1 HCV by using the Illu-
mina Human610-Quad BeadChips and observed
a common SNP (rs12979860) near IL28B (MIM 607402)
to be significantly associated with treatment response.56
In order to look for the causal variants driving this associ-
ation signal, we followed rs12979860 by using our prefer-
ential LD approach and obtained a final set of 73er 7, 2012
Table 4. Promising Candidate Causal Variants Identified by the Preferential LD Approach
Phenotype
Discovery
SNP
Number of
Final
Candidates
Candidate
SNV Rank MAF D0 r2 PLD PhastCons
Sorting
Score
Sorting
Score
p Value
HCV treatment
response
rs12979860 73 rs4803221 2 0.145 0.914 0.347 3.26 3 104 0.678 0.899 0
rs12971396 19 0.144 0.923 0.379 3.26 3 104 0.004 0.697 1.20 3 102
Plasma vWF
level
rs687621 72 rs34054981 2 0.082 0.747 0.028 3.58 3 103 0.748 0.874 1.00 3 103
rs28503257 6 0.037 0.501 0.017 1.04 3 102 0.915 0.829 1.50 3 103
rs28647808 7 0.085 0.751 0.029 3.37 3 103 0.532 0.812 2.50 3 103
rs28641026 8 0.037 0.582 0.023 5.77 3 103 0.619 0.805 3.50 3 103
Plasma vWF
level
rs4981022 10 rs6615 1 0.127 0.950 0.058 3.15 3 103 0.998 0.955 5.00 3 104
rs117801489 3 0.015 0.848 0.024 1.92 3 103 0.862 0.932 1.50 3 103
Plasma fibrinogen
level
rs511154 21 rs34901937 1 0.093 0.764 0.180 2.45 3 104 0.882 0.961 1.50 3 103
Late-onset
Alzheimer
disease
rs11767557 16 rs73154206 1 0.019 0.919 0.060 1.34 3 103 0.956 0.968 1.00 3 103
rs11552742 2 0.008 1.000 0.029 5.14 3 103 0.962 0.917 2.00 3 103
The following abbreviations are used: SNV, single-nucleotide variant; MAF, minor allele frequency; PLD, preferential linkage disequilibrium; and vWF, von Wille-
brand factor.candidates (Table 4). We imputed their genotypes from our
sequenced samples to the same European-American GWAS
cohort used by Ge et al.,56 and we tested the association
between the candidates and the phenotype. Although
the second-best candidate, rs4803221 (MAF ¼ 14.49%),
was not well imputed in our GWAS cohort (MACH-esti-
mated r2 ¼ 0.43), it has been reported recently to predict
treatment response better than the discovery SNP,
rs1297986057 (MAF ¼ 28.57%). Fifteen candidate SNVs
can be well imputed (MACH-estimated r2 R 0.8), and the
candidate SNV, rs12971396, which was ranked 19th among
all 73 candidates, is much rarer than rs12979860 but has
a stronger association with the treatment response
(MAF ¼ 14.38%, p value ¼ 5.79 3 1026, and OR ¼ 5.546
for rs12971396; MAF ¼ 28.57%, p value ¼ 1.07 3 1025,
and OR ¼ 4.198 for rs12979860). Although rs12971396 is
only weakly linked to rs12979860 (r2 ¼ 0.38), it can
explain a large portion of the association between
rs12979860 and the treatment response (i.e., after
rs12971396 was accounted for, the association with
rs12979860 dropped from p ¼ 1.07 3 1025 to p ¼
1.173 107). Two parallel GWASs in Australian58 and Japa-
nese59 populations have identified another SNP,
rs8099917, at the IL28B locus to be significantly associated
with the HCV treatment response. The candidate SNV,
rs12971396, was found to be strongly linked to
rs8099917 (r2¼ 0.84) and completely explained the associ-
ation between rs8099917 and treatment response (the
p value increased from 4.07 3 1025 to 0.88 after
rs12971396 was accounted for in the GWAS cohort used
by Ge et al.56).
Plasma Level of Coagulation Factors
Smith et al. carried out a meta-GWAS on the plasma levels
of coagulation factors VII (FVII), VIII (FVIII), and von Wil-The Americanlebrand factor (vWF).60 They observed rs687621 in ABO
(MIM 110300) to be significantly associated with the
vWF level. By using our preferential LD approach to follow
this discovery SNP, we found a total of 72 candidate SNVs,
of which four coding SNVs in ADAMTS13 (MIM 604134)
fell within the top 10; these included two nonsynonymous
SNVs (rs28503257 and rs28647808) and two synonymous
SNVs (rs34054981 and rs28641026) (Table 4). The two
nonsynonymous SNVs were predicted to be probably
damaging by PolyPhen2.61,62 ADAMTS13 encodes a vWF-
cleaving protease, which cleaves vWF at the peptide
bond between Tyr842 and Met843. Such ADAMTS13-
dependent proteolysis decreases the size, as well as the pro-
thrombotic activity, of the vWF multimer. Deficiency of
ADAMTS13 leaves the uncleaved and highly thrombotic
vWF to accumulate in the plasma and results in thrombo-
embolism.63 These candidate coding causal variants in
ADAMTS13 might affect the efficiency of the enzyme
activity and might therefore cause changes in the plasma
vWF level. A common intronic SNP (rs4981022) in
STAB2 (MIM 608561) was also found to significantly asso-
ciate with the plasma vWF level by Smith et al. Application
of the preferential LD approach to this discovery SNP led to
the identification of ten candidate causal SNVs. The best
candidate, rs6615, is a synonymous SNV in HSP90B1
(MIM 191175) (also called GP96 or GRP94), which encodes
a chaperone in the endoplasmic reticulum (ER). Protein
interaction between HSP90B1 and vWF has been docu-
mented before.64,65 HSP90B1 is also known to chaperone
GPIX in the ER and is required for its proper folding and
the subsequent assembly of the GPIb-IX-IV complex,
which is the receptor of vWF and is essential for vWF-
mediated platelet activation.66 rs6615 might directly
modulate vWF levels by affecting its chaperone functionJournal of Human Genetics 91, 422–434, September 7, 2012 429
on vWF, or it might indirectly alter vWF levels by affecting
the assembly of the vWF receptor. The third candidate,
rs117801489, is a nonsynonymous SNV in GLT8D2, and
it is predicted to be probably damaging to GLT8D2 by
PolyPhen2. GLT8D2 encodes a glycosyltransferase
belonging to glycosyltransferase family 8. Two members
(GXYLT1 and GXYLT2) of the same family can transfer
xylose to O-linked glucose,67 and the O-linked glycosyla-
tion of vWF was reported to associate with plasma vWF
levels.68 It is possible that vWF is a target of GLT8D2 glyco-
syltransferase and that rs117801489 affects the glycosyla-
tion of vWF by GLT8D2 and therefore alters the plasma
vWF level.
In addition, we applied our approach to the discovery
SNP identified by a meta-GWAS on plasma fibrinogen
levels (rs511154),69 which is a noncoding SNP 18 kb
upstream of PCCB (MIM 232050), and 21 candidate causal
variants were identified. A nonsynonymous SNV
(rs34901937) in PPP2R3A (MIM 604944) was ranked as
the best candidate (Table 4). PPP2R3A encodes one of the
regulatory subunits of the protein phosphatase 2 (PP2),
which is known to regulate the platelet integrin aIIbb3
adhesion to fibrinogen.70 Although this nonsynonymous
SNV was predicted to be benign by PolyPhen2, it would
still be interesting to explore whether this SNV can disrupt
the regulatory PP2 subunit encoded by PPP2R3A and can
therefore affect the binding of fibrinogen with integrin
aIIbb3 and change the plasma fibrinogen level.
Alzheimer Disease
A recent GWAS of late-onset AD was carried out by the Alz-
heimer Disease Genetics Consortium and led to the identi-
fication of four new susceptibility loci, including EPHA1
(MIM 179610).71 We followed the most significant SNP
(rs11767557), which is about 3 kb upstream of EPHA1,
and identified two rare SNVs in ZYX (MIM 602002) as
the best two candidates (Table 4). These two candidate
causal variants include one nonsynonymous SNV
(rs73154206) predicted to be probably damaging by Poly-
Phen2 and one synonymous SNV (rs11552742). ZYX was
found to be deacetylated by SIRT1,72 which can protect
neurons from neurodegeneration in mouse models of
AD.73 It is possible that the identified candidate causal vari-
ants affect the onset of AD through the antiapoptotic
pathway involving both ZYX and SIRT1.Discussion
We describe here a computational method, the preferential
LD approach, designed to identify candidate causal vari-
ants responsible for the association between phenotypes
and GWAS-discovered SNPs. Our approach seeks to make
effective the combined use of the existing GWAS signals
and the rapidly accumulating database of sequenced
genomes. One unique advantage of this approach is its
ability to identify causal variants that are rare in the popu-
lation and that are only in weak LD with the discovery430 The American Journal of Human Genetics 91, 422–434, SeptembSNP as measured by r2. Using this approach, we were able
to rediscover known causal variants for Crohn disease,
HCV-treatment-induced hemolytic anemia, therapeutic
warfarin dose, bladder cancer, and hearing loss. These
include both cases in which the causal variant is a single
rarer variant and in which multiple rarer variants
contribute to the GWAS signal. Because of our constraints
on the MAF of the candidate SNVs, we might miss the
causal variants that are very common but are in strong
LD with the GWAS discovery SNPs. Because this scenario
is amenable to more ‘‘straightforward’’ fine-mapping
efforts and the simple r2 can work quite well in prioritizing
the common causal variant (Table S5), we did not attempt
to address it here. Instead, we focused on the scenarios in
which the causal variants are rarer because methods for
detecting the causal variants in these scenarios are limited.
We found that the preferential LD approach was able to
identify common causal variants strongly linked with the
GWAS-discovered SNP when the MAF requirements of
candidate SNVs were relaxed (Table S5). Users can change
the parameters of the preferential LD approach according
to their specific cases.
The preferential LD approach utilized genotypes from
a general population of European ancestry and can be
easily applied to existing GWASs involving this popula-
tion. We showed that this approach has led to the identifi-
cation of a number of promising causal variant candidates,
upon which testable hypotheses could be formed.
The current implementation of the preferential LD
approach might fail to identify the causal variants if they
are not SNVs, if the variants are too rare to be represented
in our discovery samples, or if the LD structure in our
samples is significantly different from the LD structure in
the original GWAS cohort. The current genotype informa-
tion used by the preferential LD approach includes only
SNVs, and we plan to include the genotypes of insertions
and deletions (indels) in the future to be able to identify in-
del causal variants. Our current collection of genotypes
comes from 75 whole-genome-sequenced individuals and
404 whole-exome-sequenced individuals, plus additional
chip genotyping and in silico imputation. As next-genera-
tion sequencing becomes routine, more and more deep-
sequenced genomes will become available. We expect
that increasing the sample size of the population used by
the preferential LD approach will boost its power to iden-
tify rarer causal variants. For example, using 800 whole-
genome samples will give us about 80% power to detect
variants with MAF R 0.1% in the general population
(Figure S1). Currently, it is a common practice to utilize
a general population for the calculation of LD between
variants (e.g., the International HapMap Project and the
1000 Genomes Project).74 Therefore, we expect that the
LDmeasures for most variants will remain similar between
the general population that we used and the respective
GWAS cohorts of European ancestry.
As the number of sequenced samples grows, the prefer-
ential LD approachwill be able to provide a comprehensiveer 7, 2012
listing of candidate causal variants for all GWAS discovery
variants and represent a general tool for leveraging GWAS
signals in the interpretation of human sequence data.Supplemental Data
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